Cancer News and Research

Latest Cancer News and Research

TTI enters into definitive license agreement with Biogen Idec

Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec , granting the latter exclusive worldwide rights to one of Trillium's development programs.

12 Jan 2010

Thames Valley Cancer Network implements ARIA system for Medical Oncology

A chemotherapy software solution that enables patients to become more involved in managing their own care has been successfully rolled out across a network of hospitals in the UK. The Thames Valley Cancer Network has implemented Aria for Medical Oncology™ from Varian Medical Systems and already has more than 850 clinical staff routinely using the system.

12 Jan 2010

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

A $1 million grant from Abraxis Bioscience, Inc. to a world-famous research laboratory at John Wayne Cancer Institute at Saint John’s Health Center could help save lives of cancer patients by helping doctors more rapidly assess whether a treatment is working or not.

12 Jan 2010

Phase I clinical trial of XRX-001 for yellow fever initiated

Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.

12 Jan 2010

Enrollment complete in Dune Medical Devices' MarginProbe pivotal clinical trial

Dune Medical Devices today announced the completion of patient enrollment in the MarginProbe™ pivotal clinical trial. The MarginProbe procedure provides surgeons with real-time detection of cancer at the edges of the tissue removed during breast conservation surgery (BCS), which is the only way to ensure the complete removal of the tumor from the breast. The randomized, controlled trial includes 664 women who underwent BCS at one of 21 leading medical facilities, with 18 in the US and three in Israel.

12 Jan 2010

Life Technologies to acquire AcroMetrix

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has signed a definitive agreement to acquire AcroMetrix, for an undisclosed amount.

12 Jan 2010

3D structure of PI3Kdelta: An important drug target for a wide range of diseases

Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.

12 Jan 2010

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.

12 Jan 2010

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

With today's release of a landmark study by the Institute of Medicine (IOM), Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C, finding that inadequate public-health resources are being allocated to national and local prevention, control, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) today renewed its call for the Administration, Congress, and the entire health care system to take immediate and decisive action to implement the report's key recommendations.

12 Jan 2010

Spinal cement may help multiple myeloma patients live longer

New technologies used to repair spinal fractures could soon be helping patients suffering from the bone marrow cancer multiple myeloma.

12 Jan 2010

Obese patients at greater risk of developing renal cell cancer

Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI.

12 Jan 2010

Ubiquitin-conjugating enzyme promotes chromosome missegregation and tumor formation

A ubiquitin-conjugating enzyme that regulates the cell cycle promotes chromosome missegregation and tumor formation, according to van Ree et al. in the January 11 issue of the Journal of Cell Biology (www.jcb.org).

12 Jan 2010

University Hospitals in Cleveland selects Sectra as PACS provider

University Hospitals in Cleveland, Ohio has selected the IT and medical-technology company Sectra as their PACS provider. University Hospitals has been recognized by Thomson Reuters as a Top 10 hospital system in the U.S., and by U.S. News and World Report as one of America’s best hospitals.

12 Jan 2010

Cancer News and Research

Latest Cancer News and Research

TTI enters into definitive license agreement with Biogen Idec

Thames Valley Cancer Network implements ARIA system for Medical Oncology

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

Phase I clinical trial of XRX-001 for yellow fever initiated

Enrollment complete in Dune Medical Devices' MarginProbe pivotal clinical trial

Life Technologies to acquire AcroMetrix

3D structure of PI3Kdelta: An important drug target for a wide range of diseases

Older patients with acute myeloid leukemia may benefit from decitabine drug

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

VentiRx Pharmaceuticals completes $25 million Series A Extension

MedGenesis Therapeutix enters into license agreement with Amgen

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

Spinal cement may help multiple myeloma patients live longer

Obese patients at greater risk of developing renal cell cancer

Ubiquitin-conjugating enzyme promotes chromosome missegregation and tumor formation

University Hospitals in Cleveland selects Sectra as PACS provider

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in